Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.08 – $0.97
27% from low
Exchange
OTC Link
OS
Borrow rate
7.11%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.5M | $94.6M | $95.2M | $96.1M | $74.1M | $63.2M | $49.7M | $49.9M |
| Cost of revenue | $17.2M | $44.0M | $43.0M | $47.5M | $54.7M | $27.6M | $28.4M | $28.2M |
| Gross profit | $52.3M | $50.6M | $52.3M | $48.6M | $19.4M | $35.6M | $21.3M | $21.7M |
| Gross margin | 75.3% | 53.5% | 54.9% | 50.6% | 26.2% | 56.3% | 42.8% | 43.5% |
| R&D | $837.0K | $1.8M | $6.0M | $5.5M | $3.3M | $3.0M | $2.2M | $1.8M |
| Operating income | $15.0M | −$24.8M | −$52.5M | $39.5M | −$50.6M | −$40.6M | −$32.0M | −$20.3M |
| EBITDA | $16.4M | −$16.8M | −$40.6M | −$38.0M | −$42.0M | −$24.9M | −$22.0M | −$13.9M |
| Net income | $11.8M | −$15.6M | −$47.2M | −$137.7M | −$59.3M | −$23.8M | −$29.8M | −$29.7M |
| Net margin | 17.0% | -16.5% | -49.6% | -143.3% | -80.0% | -37.7% | -60.1% | -59.6% |
| EPS (diluted) | 0.12 | -0.16 | -0.38 | -0.98 | -0.40 | -0.16 | -0.19 | -0.19 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $48M | $-0.15 | $-0.15–$-0.15 | 1 |
| 2027 | $73M | $0.01 | $0.01–$0.01 | 1 |
| 2028 | $79M | $0.03 | $0.03–$0.03 | 1 |
Forward consensus · source: Financial Modeling Prep
CHARLOTTES WEB HLDGS INC
No one on the platform currently holds CWBHF.
No tracked institution reports a position in CWBHF as of their last filing.
No one on the platform has traded CWBHF yet.
| $378874 |
| — |
| FNCHFinch Therapeutics Group, Inc. | $8.70 | +16.00% | $14M | — |
| GBLPGlobal Pharmatech, Inc. | $0.08 | +0.00% | $33M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.0× sales vs its 0.8× historical median P/S.
Fair value ≈ $0.24 · price $0.32 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CWBHF quarter over tomorrow. One month into the pilot program. Interesting to see in a couple of weeks how much they sold into it.
View on StockTwits ↗$CWBHF love to know how much they sold in California before yesterday. Love mine.
View on StockTwits ↗$CWBHF MASLD, formerly known as nonalcoholic fatty liver disease, is a growing global health concern and is commonly linked to obesity, insulin resistance, high sugar intake and broader metabolic problems. https://themarijuanaherald.com/2026/06/full-spectrum-cannabis-oil-with-cbd-and-thc-prevents-early-liver-damage-in-diet-induced-disease-model-study-finds/
View on StockTwits ↗$CWBHF https://themarijuanaherald.com/2026/06/cannabidiol-reduced-brain-injury-and-cognitive-deficits-following-tbi-in-new-study/
View on StockTwits ↗$CWBHF hopefully they sold a bunch to California ladt couple of days. Dont see sales figures on website.
View on StockTwits ↗$CWBHF https://www.charlottesweb.com/collections/the-california-collection
View on StockTwits ↗$CWBHF looks like they may sell a bunch before tuesday?????
View on StockTwits ↗$CWBHF another Friday press release. Last one was a little bit of good news after the close? This one slightly negative before the close?????? I guess it’s not for me to understand.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.